Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia

Published:2020-12 Issue:7 Volume:127 Page:1039-1048
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Badar Talha¹^ORCID,Szabo Aniko¹,Dinner Shira²,Liedtke Michaela³,Burkart Madelyn²,Shallis Rory M.⁴,Yurkiewicz Ilana R.³,Kuo Eric³,Khan Muhammad Ali¹,Balasubramanian Suresh⁵,Yang Jay⁵,Hefazi Mehrdad⁶^ORCID,Podoltsev Nikolai⁴^ORCID,Patel Anand⁷^ORCID,Curran Emily⁷,Wang Amy⁷,Arslan Shukaib⁸,Aldoss Ibrahim⁸,Siebenaller Caitlin⁹,Mattison Ryan J.¹⁰,Litzow Mark R.⁶,Wadleigh Martha¹¹,Advani Anjali S.⁹,Atallah Ehab¹

Affiliation:

1. Division of Hematology and Oncology Medical College of Wisconsin Milwaukee Wisconsin

2. Robert H. Lurie Comprehensive Cancer Center Northwestern Hospital Chicago Illinois

3. Stanford University Cancer Center Stanford California

4. Section of Hematology Department of Internal Medicine Yale School of Medicine New Haven Connecticut

5. Karmanos Cancer Institute Detroit Michigan

6. Division of Hematology Mayo Clinic Rochester Minnesota

7. Section of Hematology/Oncology Department of Medicine University of Chicago Chicago Illinois

8. Department of Hematology and Hematopoietic Cell Transplantation City of Hope Duarte California

9. Department of Hematology and Medical Oncology Taussig Cancer InstituteCleveland Clinic Cleveland Ohio

10. Carbone Cancer Center University of Wisconsin Madison Wisconsin

11. Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33340

Reference17 articles.

1. National Cancer Institute.Cancer Stat Facts: Leukemia—Acute Lymphocytic Leukemia (ALL). Accessed March 29 2020.https://seer.cancer.gov/statfacts/html/alyl.html

2. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

3. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration

4. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

5. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients;Current Treatment Options in Oncology;2024-06-25

2. Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study;Leukemia & Lymphoma;2024-04-17

3. Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting;Journal of Comparative Effectiveness Research;2024-02

4. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission;Blood;2024-02-01

5. Adult Acute Lymphocytic Leukemia: Strategies for Selection of Consolidation Therapy;Journal of the National Comprehensive Cancer Network;2023-11-25